Semax and Selank on TikTok: What the research actually supports

A recent TikTok video from a peptide vendor shows two vials side by side, with the caption “Yesterday Selank. Today... Semax.” The implication is that these two peptides are natural companions for cognitive enhancement, and that using them on consecutive days is a sensible protocol. But what does the research actually say about Semax and Selank, and does the pairing hold up to scrutiny?

What the clip is claiming

The clip implies that Semax and Selank are interchangeable or complementary nootropics, and that a user might cycle them daily. It does not explain what each peptide does, why they might be paired, or what evidence supports such a regimen. The casual tone suggests that this is a routine, well-established practice, but the research story is more nuanced.

What the research neighborhood actually covers

Semax and Selank are both synthetic peptides derived from naturally occurring proteins in the brain. Semax is a fragment of adrenocorticotropic hormone (ACTH) that has been studied in Russia for its potential to enhance attention, learning, and memory, particularly in the context of stroke recovery and cognitive decline. Selank is a synthetic analog of tuftsin, a peptide with immunomodulatory properties, and has been investigated for its anxiolytic (anti-anxiety) effects and its ability to modulate the breakdown of enkephalins, which are involved in pain and mood regulation.

Peer-reviewed studies, many from Russian research groups, have reported positive effects on cognitive function and anxiety in animal models and small human trials. However, these studies are often limited by small sample sizes, and many are not replicated in Western laboratories. The mechanisms of action are not fully understood, and the long-term safety profile is not well characterized.

Limits, missing context, and what a 15-second clip cannot show

A 15-second video cannot convey the complexity of peptide research. It does not mention that Semax and Selank are typically administered intranasally, not injected, and that dosing protocols vary widely. It does not address potential side effects, drug interactions, or the fact that these peptides are not approved by regulatory agencies like the FDA for any medical use. The clip also fails to note that the evidence base is largely from a specific geographic region and may not generalize to other populations.

Moreover, the pairing of Semax and Selank is not a standard combination found in the literature. While some researchers have explored their combined use, the evidence for a synergistic effect is preliminary at best. The clip's implication that they are a routine stack is not supported by robust clinical data.

How this maps to named research compounds

Semax and Selank are both available in the research-use catalog. They are distinct compounds with different proposed mechanisms: Semax is often categorized as a nootropic, while Selank is more often described as an anxiolytic. Researchers interested in these peptides should consult the primary literature for dosing and administration guidance, as there is no consensus protocol. The catalog also includes other peptides that are sometimes discussed in nootropic contexts, but no direct comparison is made in the clip.

Research-use caveat

All peptides in the catalog are intended for laboratory research and in vitro studies only. They are not approved for human or veterinary use. Researchers must handle these compounds with appropriate safety precautions and adhere to all applicable regulations. The information presented here is for educational purposes and does not constitute medical advice.